Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals' stock has increased significantly in the past six months, with a 98.70% increase and a 488.3% surge over the past year. On November 25, 2025, the U.S. FDA approved REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS). On February 5, 2026, the company reported Q1 2026 earnings, with shares declining 0.2% the day after the announcement. On April 24, 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use (EMA CHMP) adopted a positive opinion recommending approval of REDEMPLO in Europe. On May 1, 2026, Arrowhead announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals for ARO-PNPLA3, including a $25 million upfront payment and potential milestones up to $975 million. On May 7, 2026, the company reported Q2 2026 earnings, with shares declining 0.78% in aftermarket trading despite beating EPS and revenue forecasts, highlighting accelerating commercial uptake for REDEMPLO, with over 400 prescriptions since launch and a 40% increase in the four weeks leading up to May 7, 2026. Topline results from Phase 3 SHASTA-3 and SHASTA-4 studies for plozasiran in severe hypertriglyceridemia (SHTG) are expected in Q3 2026.

While Arrowhead Pharmaceuticals' primary commercial product, REDEMPLO, targets chronic conditions that may not exhibit direct seasonal demand fluctuations, the broader biotechnology sector can show cyclical patterns. Historically, the biotech industry has experienced favorable periods in months such as June, July, August, and November. Q1 earnings tend to be weaker for biopharma, while summer months can see a downturn due to regulatory delays and a lack of catalysts. The timing of clinical trial readouts and regulatory decisions could indirectly impact investor sentiment and the company's stock performance.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative medicines that treat intractable diseases by silencing the genes responsible for them, operating within the Healthcare sector and Biotechnology industry. It utilizes a proprietary Targeted RNAi Molecule (TRiM™) platform to trigger the natural RNA interference (RNAi) mechanism, enabling the rapid, deep, and durable knockdown of target genes. The company's therapeutic focus areas include cardiometabolic, pulmonary, liver, muscle, and central nervous system diseases. Key products include REDEMPLO (plozasiran), approved for Familial Chylomicronemia Syndrome (FCS), Zodasiran (ARO-ANG3) for Homozygous Familial Hypercholesterolemia (HoFH), ARO-RAGE for lung diseases, and ARO-PNPLA3 for metabolic dysfunction-associated steatohepatitis (MASH), which was recently licensed to Madrigal Pharmaceuticals. Other pipeline candidates include ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-DUX4, ARO-SOD1, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, ARO-ENaC, ARO-SNCA (licensed to Novartis for Parkinson's disease), ARO-MAPT (for tauopathies like Alzheimer's disease), ARO-DIMER-PA, ARO-INHBE, and ARO-ALK7.

Arrowhead Pharmaceuticals is headquartered in Pasadena, California, with a research facility in Madison, Wisconsin, United States. The company is expanding its international presence, with REDEMPLO having received regulatory approvals or positive opinions in Canada, Australia, China, and Europe, with launches anticipated in these regions.

Arrowhead Pharmaceuticals' brand reputation has been positively impacted by the FDA approval of REDEMPLO in November 2025, marking the first FDA-approved siRNA medicine leveraging Arrowhead's TRiM™ platform. Subsequent regulatory approvals and positive opinions for REDEMPLO in Canada, Australia, China, and Europe further bolster its reputation and global reach. The company is seen as a leader in RNAi therapeutics with a robust pipeline and a focus on innovative scientific methods. Analyst sentiment is generally bullish, with a consensus rating of "Buy". A potential event that could affect reputation is a high-stakes patent dispute with Ionis Pharmaceuticals over plozasiran.

Arrowhead Pharmaceuticals has a mixed ownership structure, including institutional, retail, and individual investors. As of May 1, 2026, there are 416 institutional owners holding a total of 115,577,357 shares, with major institutional shareholders including BlackRock, Inc., Vanguard Group Inc, Avoro Capital Advisors LLC, Fmr Llc, State Street Corp, Geode Capital Management, Llc, Slate Path Capital LP, Baker Bros. Advisors Lp, Arrowstreet Capital, Limited Partnership, and Fred Alger Management, Llc. David M. Knott is the largest individual shareholder, owning 5.61 million shares, representing 3.98% of the company, and insiders collectively own approximately 3.68% of the company's stock.